Publications

Meyer C, Price S, Ercumen A. 2024. Do animal husbandry operations contaminate groundwater sources with antimicrobial resistance: Systematic review. Environ Sci Pollut Res Int 31(11):16164–16176; doi: 10.1007/s11356-024-31899-w. PMID: 38321277.

Racz L, Gauthier A, Bare J, Heintz M, Feifarek D, Kennedy S, Panko J. 2024. Assessment of perfluorocarboxylic acids in fluorinated high-density polyethylene containers and estimation of potential non-cancer risks associated with anticipated use scenarios. Regul Toxicol Pharmacol 147(Feb):105560; doi: 10.1016/j.yrtph.2024.105560. PMID: 38182014.

Fitch S, Blanchette A, Haws LC, Franke K, Ring C, DeVito M, Wheeler M,… Wikoff DS. 2024. Systematic update to the mammalian relative potency estimate database and development of best estimate toxic equivalency factors for dioxin-like compounds. Regul Toxicol Pharmacol 147(Feb):105571; doi: 10.1016/j.yrtph.2024.105571. PMID: 38244664.

Russell AJ, Vincent M, Buerger AN, Dotson S, Lotter J, Maier A. 2024. Establishing short-term occupational exposure limits (STELs) for sensory irritants using predictive and in silico respiratory rate depression (RD50) models. Inhal Toxicol 36(1):13-25; doi: 10.1080/08958378.2023.2299867. PMID: 38252504.

Pochron ST, Sasoun S, Maharjan S, Pirzada WU, Byrne S, Girgis M, Jacobellis MA, Mitra JA, et al. 2024. Toxicity of a common glyphosate metabolite to the freshwater planarian (Girardia tigrina). Sustainability 16(2):842; doi: 10.3390/su16020842.

Bak A, Burlage R, Greene N, Nambiar P, Lu X, Templeton A. 2024. Accelerating drug product development and approval: Early development and evaluation. Pharm Res 41(1):1-6; doi: 10.1007/s11095-023-03566-1. PMID: 37552384.

Davies S, Boller E, Chase J, Beaubrun A, Miller C, Jensen I. 2024. A cost-consequence analysis of the Xpert Xpress CoV-2/Flu/RSV plus test strategy for the diagnosis of influenza-like illnesses. J Med Econ 27(1):430–441; doi: 10.1080/13696998.2024.2313391. PMID: 38328858.

Wagner TD, Westrich KD, Nordyke RJ, Campbell JD. 2024. Inflation-adjusted analysis of ICER’s Unsupported Price Increase reports: Contextualizing drug spending changes. J Med Econ 27(1):1537-1541; doi: 10.1080/13696998.2024.2428109. PMID: 39626873.

Rana ZH, Frankenfeld C, Kennedy E, Bertoldo J, de Jonge E, Cheskin LJ. 2024. Why don’t college freshmen meet the US Dietary Guidelines for added sugar, refined grains, sodium, and saturated fat? J Am Coll Health 72(1):142-152; doi: 10.1080/07448481.2021.2024213. PMID: 35080478.

DeVito M, Bokkers B, van Duursen MBM, van Ede K, Feeley M, Antunes Fernandes Gaspar E, Haws L,… Wheeler M,… Wikoff D, et al. 2024. The 2022 World Health Organization reevaluation of human and mammalian toxic equivalency factors for polychlorinated dioxins, dibenzofurans and biphenyls. Regul Toxicol Pharmacol 146(Jan):105525; doi: 10.1016/j.yrtph.2023.105525. PMID: 37972849.

Movva N, Reichert H, Hooda N, Bylsma LC, Mitchell M, Cohen SS. 2023. Dietary eating patterns, dairy consumption, and anxiety: A systematic literature review. PLoS One 18(12):e0295975. doi: 10.1371/journal.pone.0295975. PMID: 38153944.

Moyer H, Kim S, Lam BP, Valdiviezo A, Richardson L, Menon R, Rusyn I, Han A. Evaluating mechanistic underpinnings of environmental chemical effects on feto-maternal interface using a human organ-on-chip model. Lonestar Society of Toxicology Meeting, Houston, TX, December 2023.

Garrison K, Zhang W, Jensen I, Shah A, Brown S, Stephenson B, Yim C. Cost-utility analysis of roflumilast cream for plaque psoriasis, including intertriginous, from the Canadian societal perspective. Abstract EE303, ISPOR EU 2023.

Gutierrez M, Wild S, Compton A, Paine E, Jensen I, Shah A. Cost consequences of using clevidipine in neurological emergencies from the perspective of a US hospital. Abstract EE579, ISPOR EU 2023.

Gutierrez M, Wild S, Compton A, Paine E, Jensen I, Shah A. Cost consequences of using clevidipine in cardiac surgery from the perspective of a US hospital. Abstract EE734, ISPOR EU 2023.

Gutierrez M, Wild S, Compton A, Paine E, Jensen I, Shah A. Cost consequences of using clevidipine in acute hypertension from the perspective of a US hospital. Abstract EE125, ISPOR EU 2023.

Wikoff D, Ring C, DeVito M, Walker N, Birnbaum L, Haws L. 2023. Development and application of a systematic and quantitative weighting framework to evaluate the quality and relevance of relative potency estimates for dioxin-like compounds (DLCs) for human health risk assessment. Regul Toxicol Pharmacol 145(Dec):105500; doi: 10.1016/j.yrtph.2023.105500. PMID: 37866700.

Bean K, Miller B, Jensen I, Howle K, Wilds A, Walz M, et al. The societal costs of metachromatic leukodystrophy (MLD) in the United States. Abstract EE547, ISPOR EU 2023.

Miller B, Russel-Szymczyk M, Jensen I, Shah A, Alexopoulos T, Herbert A, et al. Cost-consequence of cladribine tablets for the treatment of highly-active relapsing-remitting multiple sclerosis (RRMS) in the UK. Abstract EE658, ISPOR EU 2023.

Flannery BM, Turley AE, Anyangwe N, Mattia A, Whiteside C, Hermansky S, Schaefer HR, Tyler T, Fitzpatrick SC. 2023. Retrospective analysis of dog study data from food and color additive petitions. Regul Toxicol Pharmacol 145(Dec):105523; doi: 10.1016/j.yrtph.2023.105523. PMID: 37956767.